OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Kim on Data for NT-I7 Plus Pembrolizumab in Pretreated Advanced MSS CRC and PDAC

July 3rd 2024

Richard Kim, MD, on efficacy data for NT-I7 plus pembrolizumab in pretreated microsatellite stable colorectal cancer and pancreatic ductal adenocarcinoma.

Dr Tarantino on the Safety of T-DXd and T-DM1 in HER2+ Breast Cancer

July 2nd 2024

Paolo Tarantino, MD, discusses updated safety data from the phase 3 DESTINY-Breast03 trial of T-DXd in HER2+ breast cancer.

Dr Davis on the Potential For ADCs to Continue to Reshape Breast Cancer Treatment

July 2nd 2024

Andrew Davis, MD, discusses how antibody-drug conjugates could continue to reshape the breast cancer treatment paradigm.

Dr Khushalani on Fixed-Dose Treatment Regimens in Advanced Melanoma

July 2nd 2024

Nikhil Khushalani, MD, discusses the benefits and limitations of fixed-dose treatment regimens in patients with unresectable or metastatic melanoma.

Dr Cherng on Considerations for the Use of Bispecific Antibodies in DLBCL

July 2nd 2024

Hua-Jay “Jeff” Cherng, MD, discusses efficacy and safety considerations for the use of bispecific antibodies in patients with DLBCL.

Dr Evans on the Influence on Patient Factors and Treatment Decisions in Pancreatic Cancer

July 2nd 2024

Nicole S. Evans, MD, discusses the influence of patient factors on declining treatment in pancreatic cancer.

Dr Bardia on the Limitations of HER2 Testing Assays in HER2-Low and -Ultralow Breast Cancer

July 2nd 2024

Aditya Bardia, MD, MPH, FASCO, discusses HER2 IHC testing in patients with HER2-low and -ultralow metastatic breast cancer.

Dr Mohty on the Implications of Real-World Efficacy With Elranatamab in R/R Myeloma

July 2nd 2024

Mohamad Mohty, MD, PhD, shares the rationale for investigating the real-world efficacy of elranatamab in relapsed/refractory multiple myeloma.

Dr Hunter on the Evolution of Pathology in Myelofibrosis

July 2nd 2024

Anthony M. Hunter, MD, discusses the evolution of pathology in myelofibrosis based on outcomes from clinical trials.

Dr Mujumdar on Key Trials Evaluating Treatments for Ovarian Cancer

July 2nd 2024

Vaidehi Mujumdar, MD, discusses several key trials that have helped shift the ovarian cancer treatment paradigm.

Dr Punekar on the Evaluation of NT-112 in KRAS G12D+ Advanced Solid Tumors

July 2nd 2024

Salman R. Punekar, MD discusses the rationale for evaluating safety and preliminary anti-tumor activity of NT-112 in solid tumors with the KRAS G12D mutation.

Dr Lin on the Efficacy and Safety of Taletrectinib in ROS1 Fusion+ NSCLC

July 2nd 2024

Jessica Lin, MD, discusses key findings from the phase 2 TRUST-I trial in patients with ROS1 fusion–positive NSCLC.

Dr Daver on the Initial Safety of DSP-5336 in Relapsed/Refractory Acute Leukemia

July 1st 2024

Naval G. Daver, MD, discusses updated findings from a phase 1/2 study of the menin-MLL inhibitor DSP-5336 in relapsed/refractory acute leukemias.

Dr Kamdar on the TRANSCEND NHL 001 Trial of Liso-Cel in Relapsed/Refractory MCL

July 1st 2024

Manali Kamdar, MD, discusses the patient population included in the mantle cell lymphoma cohort of the phase 3 TRANSCEND NHL 001 trial.

Dr Garcia-Manero on the Impact of Luspatercept on Hematopoietic Lineages in Lower-Risk MDS

July 1st 2024

Guillermo Garcia-Manero, MD, discusses the safety and impact of luspatercept on hematopoetic lineages in transfusion-dependent lower-risk MDS.

Dr Jhaveri on the Implications of DESTINY-Breast06 for HR+/HER2-Low and -Ultralow Breast Cancer

July 1st 2024

Komal Jhaveri, MD, FACP, discusses the implications of the DESTINY-Breast06 trial for hormone receptor–positive, HER2-low and -ultralow breast cancer.

Dr Mouabbi on the Use of Ribociclib vs Abemaciclib in HR+/HER2– Breast Cancer

June 28th 2024

Jason Abdou Mouabbi, MD, discusses considerations for the use of ribociclib vs abemaciclib in patients with HR-positive, HER2-negative breast cancer.

Dr Gong on the Frontline Use of PARP Inhibitors in mCRPC

June 28th 2024

Jun Gong, MD, discusses the variety of PARP inhibitor–based frontline treatment regimens that are FDA approved for patients with mCRPC.

Dr Phillips on the Evolution of the MCL Treatment Paradigm

June 28th 2024

Tycel Phillips, MD, discusses the evolution of treatment for patients with mantle cell lymphoma.

Dr Wirth on the Full FDA Approval of Selpercatinib for Advanced RET Fusion+ Thyroid Cancer

June 28th 2024

Lori Wirth, MD, discusses the significance of the full FDA approval of selpercatinib for patients with advanced or metastatic RET fusion+ thyroid cancer.

NEXT PAGE
PREVIOUS PAGE